Background/objective: Flexibility in sample processing may improve test utility of the quantitative antigen-specific T cell assay (T-SPOT.TB). We investigated whether delayed sample processing with and without the use of T-Cell Xtend, a proprietary reagent, impacted upon test accuracy.
Methods: Blood samples obtained from 363 sequentially recruited tuberculosis suspects or treated patients were processed immediately (day 0) and at different times after receipt of the sample [approximately 24-h (day 1) or approximately 32-h (day 2)] with and without adding T-Cell Xtend.
Results: T-Cell-Xtend-independent median ELISPOT counts (spot forming cells per million peripheral blood mononuclear cells) were significantly higher at day 1 versus day 0 (114 vs. 100; n=66; p=0.03); inter-time-point agreement between the results was 95.45% and the conversion/reversion rate was 4.55%. By contrast, counts on day 0 without T-Cell Xtend versus day 1 with T-Cell Xtend were similar (56 vs. 56; n=215), inter-time-point agreement between the results was 97.17%, and the conversion/reversion rate was 2.83%. Counts performed at day 2 with T-Cell Xtend were not significantly different from day 0. These findings were independent of HIV status.
Conclusion: There was high agreement between results when samples were processed immediately and after a 24-h delay. However, although the use of T-Cell Xtend appeared to reduce the number of conversions/reversions this reduction was not statistically significant. Larger studies are required to clarify these findings.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jinf.2010.01.012 | DOI Listing |
Clin Infect Dis
November 2024
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
J Clin Microbiol
September 2022
University of Texas Health Science Center at Houston, School of Public Health in Brownsville, Brownsville, Texas, USA.
The diagnosis of latent tuberculosis (TB) infection (LTBI) is critical to improve TB treatment and control, and the T-SPOT. test is a commercial enzyme-linked immunosorbent spot assay used for this purpose. The objective of the study was to increase automation and extend the time between blood collection and processing for the T-SPOT.
View Article and Find Full Text PDFJ Clin Microbiol
April 2021
Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
T-SPOT. (T-SPOT) is an interferon gamma release assay (IGRA) used to detect infection with based on the number of spot-forming T cells; however, delays in sample processing have been shown to reduce the number of these spots that are detected following laboratory processing. Adding T-Cell Xtend (XT) into blood samples before processing reportedly extends the amount of time allowed between blood collection and processing up to 32 h.
View Article and Find Full Text PDFTuberculosis (Edinb)
January 2018
Oxford Immunotec, 700 Nickerson Rd, Marlborough, MA 01752, USA. Electronic address:
Background: Accurate identification of individuals with TB infection, is required to achieve the WHO's End TB Strategy goals. While there is general acceptance that the T-SPOT.TB test borderline category provides an opportunity to increase test resolution of results around the test cut-off point, this has not been investigated.
View Article and Find Full Text PDFJ Clin Lab Anal
February 2018
Department of Clinical Laboratory, Chest Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, Xinjiang, China.
Background: T-cell Xtend (TCX) was introduced to extend the blood storage time for T-SPOT.TB test, a widely used commercial interferon gamma release assay (IGRA) for rapid in vitro tuberculosis.
Methods: A total of 99 Uyghur suspected tuberculosis patients were recruited in this study.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!